Probiotics may help manage childhood obesity

September 07, 2020

Probiotics may help children and adolescents with obesity lose weight when taken alongside a calorie-controlled diet, according to a study being presented at e-ECE 2020. The study found that obese children who were put on a calorie-restricted diet and given probiotics Bifidobacterium breve BR03 and Bifidobacterium breve B632, lost more weight and had improved insulin sensitivity compared with children on a diet only. These findings suggest that probiotic supplements and a calorie-controlled diet may help manage obesity in the younger population and reduce future health risks, such as heart disease and diabetes.

Obesity is a global health concern and can lead to a number of life-threatening conditions, such as diabetes and heart disease. Treatment and prevention is a serious public health challenge, especially in children and adolescents. Bifidobacteria are a group of probiotic bacteria that are part of the natural gut microbiome and help with preventing infection from other bacteria, such as E.coli, and digestion of carbohydrates and dietary fibre. During digestion, they release chemicals called short-chain fatty acids, which play an important role in gut health and controlling hunger. Low numbers of Bifodobacteria may impair digestion, affect food intake and energy expenditure, leading to body weight gain and obesity.

Previous studies suggested that probiotic supplementation with Bifidobacteria could help restore the composition of the gut microbiome, which may aid weight loss and could be a potential approach for obesity management. However, current research uses mixtures of different strains of probiotics and does not examine the effects of administering Bifidobacteria alone.

Dr Flavia Prodam and her team at the University of Piemonte Orientale, aimed to assess the impact of Bifidobacteria probiotic treatment in children and adolescents with obesity on a controlled diet, on weight loss and gut microbiota composition. 100 obese children and adolescents (6-18 years) were put on a calorie-controlled diet and randomly given either probiotics Bifidobacterium breve BR03 and Bifidobacterium breve B632, or a placebo for 8 weeks. Clinical, biochemical and stool sample analyses were carried out to determine the effect of probiotic supplementation on weight gain, gut microbiota and metabolism.

The results suggested that children who had taken probiotics had a reduction in waist circumference, BMI, insulin resistance and E.coli in their gut. These beneficial effects demonstrate the potential of probiotics in helping to treat obesity in children and adolescents, when undergoing dietary restrictions.

"Probiotic supplements are frequently given to people without proper evidence data. These findings start to give evidence of the efficacy and safety of two probiotic strains in treating obesity in a younger population," Dr Prodam comments.

The study suggests that supplementation with probiotics could modify the gut microbiome environment and beneficially affect metabolism, helping obese children or adolescents who are also undergoing a restricted diet to lose weight. However, larger studies over a longer period of time are needed to investigate this.

Dr Prodam explains, "The next step for our research is to identify patients that could benefit from this probiotic treatment, with a view to creating a more personalised weight-loss strategy. We also want to decipher more clearly the role of diet and probiotics on microbiome composition. This could help us to understand how the microbiota is different in young people with obesity."
-end-
Abstract

2167

Supplementation with Bifidobacterium breve BR03 and Bifidobacterium breve B632 favoured weight loss and improved insulin metabolism in children and adolescents with obesity in the BIFI-OBESE cross-over, randomized placebo-controlled trial

Arianna Solito, Iderina Hasballa, Matteo Calgaro, Nicole Bozzi Cionci, Roberta Ricotti, Marina Caputo, Giulia Genoni, Alice Monzani, Francesca Archero, Simonetta Bellone, Gianni Bona, Emanuela Agosti, Gianluca Aimaretti, Angela Amoruso, Marco Pane, Nicola Vitulo, Diana DI Gioia, Flavia Prodam

Background: Variations in gut microbiota might impact metabolic functions like caloric intake and energy expenditure leading to body weight excess. Microbiota modulation may be a potential approach for obesity management, especially in subject characterized by specific microbial enterotypes.

Objective: We aimed to assess the impact of probiotic treatment in obese children and adolescents, under diet control, on weight loss, glucose, and insulin homeostasis, gut microbiota composition and SCFAs.

Methods: This was a cross-over, double-blind, RCT on 100 children and adolescents (6-18 years) affected by obesity with insulin-resistance (NCT03261466). The subjects on dietary training were randomized to treatment with 2x109 CFU/AFU/die of Bifidobacterium breve BR03 (DSM 16604) and Bifidobacterium breve B632 (DSM 24706) or placebo for 8 weeks with a 4-weeks wash-out period. Clinical, biochemical and stool sample analyses were carried out at each time (T0-T3).

Results: At baseline, there were no differences in clinical and metabolic parameters between treatment and control group, except Escherichia coli concentration, which was higher in the placebo group. A mixed-effect model analysis revealed a carry-over effect on most of the variables, suggesting that the probiotic treatment had a prolonged effect over the washout period. Due to this event, only the results of the first phase (T0- T1) were deeply analyzed. For all the subjects (active and placebo) we observed significantly decreased BMI, BMI Z score, waist circumference (WC), systolic and diastolic blood pressure, insulin after OGTT, and E. Coli concentrations at T1. Probiotics further decreased WC (-3.51 cm, p<0.05), BMI Z score (-0.17 Kg/m2, p=0.07), fasting insulin (-4.57 mcUI/ml, p=0.06), HOMA IR (-1.1, p<0.05), E. Coli concentrations (p<0.02), and increased nearly to significance insulin sensitivity after OGTT. No differences were observed in inflammatory cytokines and GLP-1 levels at fasting. Of twenty-five SCFAs, probiotics decreased the 2-methyl- propanoic acid relative abundance (p<0.02). The PCoA analysis of SCFAs allowed defining four clusters of patients. Two clusters identified subjects that were healthier and had better responses in BMI Z score, WC, insulin resistance and sensitivity during probiotics.

Conclusions: Probiotic supplementation with B. breve BR03 and B632 has determined beneficial effects on weight and insulin metabolism in obese children and adolescents undergoing dietary training. Moreover, the microbiome-host configuration could be a predictor of the obesity phenotype and the efficacy of treatment with B. Breve strains.

European Society of Endocrinology

Related Obesity Articles from Brightsurf:

11 years of data add to the evidence for using testosterone therapy to treat obesity, including as an alternative to obesity surgery
New research covering 11 years of data presented at this year's European and International Congress on Obesity (ECOICO 2020) show that, in obese men suffering from hypogonadism (low testosterone), treatment with testosterone injections lowers their weight and improves a wide range of other metabolic parameters.

Overlap between immunology of COVID-19 and obesity could explain the increased risk of death in people living with obesity, and also older patients
Data presented in a special COVID-19 session at the European and International Congress on Obesity (ECOICO 2020) suggests that there are overlaps between the immunological disturbances found in both COVID-19 disease and patients with obesity, which could explain the increased disease severity and mortality risk faced by obese patients, and also elderly patients, who are infected by the SARS-CoV-2 virus that causes COVID-19 disease.

New obesity guideline: Address root causes as foundation of obesity management
besity management should focus on outcomes that patients consider to be important, not weight loss alone, and include a holistic approach that addresses the root causes of obesity, according to a new clinical practice guideline published in CMAJ (Canadian Medical Association Journal) http://www.cmaj.ca/lookup/doi/10.1503/cmaj.191707.

Changing the debate around obesity
The UK's National Health Service (NHS) needs to do more to address the ingrained stigma and discrimination faced by people with obesity, says a leading health psychologist.

Study links longer exposure to obesity and earlier development of obesity to increased risk of type 2 diabetes
Cumulative exposure to obesity could be at least as important as actually being obese in terms of risk of developing type 2 diabetes (T2D), concludes new research published in Diabetologia (the journal of the European Association for the Study of Diabetes [EASD]).

How much do obesity and addictions overlap?
A large analysis of personality studies has found that people with obesity behave somewhat like people with addictions to alcohol or drugs.

Should obesity be recognized as a disease?
With obesity now affecting almost a third (29%) of the population in England, and expected to rise to 35% by 2030, should we now recognize it as a disease?

Is obesity associated with risk of pediatric MS?
A single-center study of 453 children in Germany with multiple sclerosis (MS) investigated the association of obesity with pediatric MS risk and with the response of first-line therapy in children with MS.

Women with obesity prior to conception are more likely to have children with obesity
A systematic review and meta-analysis identified significantly increased odds of child obesity when mothers have obesity before conception, according to a study published June 11, 2019 in the open-access journal PLOS Medicine by Nicola Heslehurst of Newcastle University in the UK, and colleagues.

Obesity medicine association announces major updates to its adult obesity algorithm
The Obesity Medicine Association (OMA) announced the immediate availability of the 2019 OMA Adult Obesity Algorithm, with new information for clinicians including the relationship between Obesity and Cardiovascular Disease, Diabetes Mellitus, Dyslipidemia, and Cancer; information on investigational Anti-Obesity Pharmacotherapy; treatments for Lipodystrophy; and Pharmacokinetics and Obesity.

Read More: Obesity News and Obesity Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.